JPRN-UMIN000004107已完成1 期
The effect of Sorafenib and intermittent hepatic arterial infusion chemotherapy using Cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus : a phase 1 study - The effect of Sorafenib and intermittent HAIC using CDDP for advanced HCC with PVTT : P-1 study
Kansai Medical University Hirakata Hospital0 个研究点目标入组 18 人开始时间: 2010年9月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Presence of metastasis 2.Presence of hepatic encephalopathy 3.Patients with active bacterial infection 4.Patients having blood vessel abnormality that difficult to insert hepatic arterial infusion port 5.Patients having severe disease 6.Patients losing of control over bowel movements 7.Patients with double cance 8.During pregnancy or breast-feeding woman 9.Contraindication of sorafenib or cisplatin
研究者
相似试验
已完成
2 期
Randomized phase II study of sorafenib and hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma.advanced hepatocellular carcinomaJPRN-UMIN000005703ational Cancer Center Hospital105
已完成
1 期
Effects of Sorafenib on Intrahepatic Circulations in Patients with Advanced Hepatocullar Carcinoma: A Prospective Cohort StudyPatients with Advanced Hepatocellular CarcinomaJPRN-UMIN000005410Kitasato University East Hospital40
招募中
2 期
Maintenance Therapy of Sorafenib after Hepatic Resection for high risk recurrence hepatocellular carcinoma (MISORA)Hepatocellular CarcinomaJPRN-UMIN000013089Department of Surgery, Kyoto University35
已完成
3 期
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCCHepatocellular CarcinomaNCT02774187Sun Yat-sen University247
Unknown
3 期
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCCHepatocellular CarcinomaNCT03775395Sun Yat-sen University250